Ratings Gedeon Richter OTC Markets

Equities

RGEDF

HU0000123096

Market Closed - OTC Markets Other stock markets 09:53:33 2024-06-06 EDT			5-day change	1st Jan Change
24.9 ^USD	-5.66%		0.00%	+0.22%

06-11	Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Specific assets from Mithra Recherche Et Développement Sa.	CI
06-11	Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Its low valuation, with P/E ratio at 7.18 and 6.55 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Historically, the company has been releasing figures that are above expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GEDEON RICHTER	+0.22%	4.73B		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.39%	43.67B		B-
OTSUKA HOLDINGS CO., LTD.	+26.21%	22.79B		B+
SANDOZ GROUP AG	+21.43%	15.45B		-
CIPLA LIMITED	+18.82%	14.29B		B+
ZYDUS LIFESCIENCES LIMITED	+53.37%	12.83B		B
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
ONO PHARMACEUTICAL CO., LTD.	-11.88%	6.52B		B+
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+15.72%	5.59B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes